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Background: The E3 ubiquitin ligase Fbxw7 functions as a general tumor suppressor by targeting several
well-known oncoproteins for ubiquitination and proteasomal degradation. However, the clinical significance of
Fbxw7 and the mechanisms involved in the anti-cancer effect of Fbxw7 in HCC are not clear.
Method: The Fbxw7 and YAP expression in 60 samples of surgical resected HCC and matched normal
tumor-adjacent tissues were assessed using IHC or immunoblotting. Flow cytometry, caspase 3/7 activity assay, BrdU
cell proliferation assay and MTT assay were used to detect proliferation and apoptosis of HCC cells. The regulatory
effect of Fbxw7 on YAP in HCC cells was confirmed by qRT-PCR, immunoblotting and immunofluorescence.
Co-immunoprecipitation was used to analyze interaction between YAP and Fbxw7. Nude mice subcutaneous
injection, Ki-67 staining and TUNEL assay were used to evaluate tumor growth and apoptosis in vivo.
Results: In this study, we found that Fbxw7 expression was impaired in HCC tissues and loss of Fbxw7 expression was
correlated with poor clinicopathological features including large tumor size, venous infiltration, high pathological grading
and advanced TNM stage. Additionally, we demonstrated that patients with positive Fbxw7 expression had a better
5-year survival and Fbxw7 was an independent factor for predicting the prognosis of HCC patients. We confirmed that
Fbxw7 inhibited HCC by inducing both apoptosis and growth arrest. Elevated YAP expression was observed in the same
cohort of HCC tissues. Pearson's correlation coefficient analysis indicated that Fbxw7 was inversely associated with YAP
protein expression in HCC tissues. We also found that Fbxw7 regulated YAP protein abundance by targeting YAP for
ubiquitination and proteasomal degradation in HCC. Furthermore, restoring YAP expression partially abrogated Fbxw7
induced HCC cell apoptosis and growth arrest in vitro and in vivo.
Conclusion: These results indicate that Fbxw7 may serve as a prognostic marker and that YAP may be a potential target
of Fbxw7 in HCC.
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Fbxw7 (F-box and WD repeat domain-containing 7) also
known as Fbw7, a well-known F-box protein in the SCF
(SKP1-CUL1-F-box protein) E3 ligase complex, deter-
mines target specificity by recognizing and binding pro-
teins, leading to their ubiquitination and proteasomal
degradation [1]. Fbxw7 has been characterized as a gen-
eral tumor suppressor in human cancer and plays a crit-
ical role in cell cycle progression, apoptosis, tumor
metastasis and drug resistance [1]. Recent studies have
identified several specific substrates of Fbxw7 including
c-Myc [2], Cyclin E [3], c-Jun [4], SREBP1 (Sterol regula-
tory element binding protein-1) [5], mTOR (Mammalian
target of rapamycin) [6], Notch-1 [7] and MCL-1 (Mye-
loid cell leukemia-1) [8]. These target proteins typically
contain the conserved CPD (Cdc4 phospho-degron) (L)-
X-pT/pS-P-(P)-X-pS/pT/E/D (X = any amino acid) motif
and the amino residues in CPD must first be phosphory-
lated in order for Fbxw7 to efficiently recognize and me-
diate the ubiquitination of the target protein [1,9].
Reduced Fbxw7 expression is often observed in mul-
tiple human cancers including breast cancer, colorectal
cancer, gastric cancer, prostate cancer, pancreatic cancer
and HCC (Hepatocellular carcinoma) [10]. Akhoondi
et al. performed a comprehensive genetic screen of pri-
mary tumors. Their data showed that gene mutation
leads to Fbxw7 inactivation in various types of human
cancers, and overall mutation frequency was approxi-
mately 6% [11]. Yakobori et al. shown that low Fbxw7
expression was significantly correlated with lymph node
metastasis, tumor size and poor prognosis in gastric can-
cer [12]. Loss-of-function mutations of Fbxw7 led to the
accumulation of Cyclin E and played a key role in the
progression of human pancreatic cancer [13]. A recent
study reported that Fbxw7 inhibited melanoma cell mi-
gration and served as a prognostic marker [14]. Our pre-
vious studies have demonstrated that low Fbxw7
expression contributes to the more aggressive pheno-
types seen in HCC; Fbxw7 knockdown promoted tumor
cell proliferation and decreased p53-induced apoptosis
in vitro [15-17]. However, the clinical significance of
Fbxw7 in predicting prognosis and the mechanisms in-
volved in the anti-cancer effects of Fbxw7 are unknown.
The Hippo signaling pathway, a well-conserved potent
regulator of cell growth and apoptosis in mammals, was ini-
tially discovered in Drosophila [18]. YAP (Yes-associated
protein), a negatively regulated downstream effector of the
Hippo pathway, functions as a transcriptional coactivator,
which interacts with several transcription factors including
ErbB4, RUNX2 (Runt-related transcription factor 2), p73
and TEAD (TEA domain) transcription factor family mem-
bers [19,20]. YAP overexpression and nuclear accumulation
has been reported in various types of human cancers, in-
cluding colorectal cancer, ovarian cancer, lung cancer andHCC [21]. YAP was identified as the driving oncogene of
the 11q22 amplicon seen in HCC and breast cancer
[22,23]. Transgenic mice with liver-targeted YAP overex-
pression resulted in hepatomegaly and eventually developed
liver tumors or severe dysplasia [24]. In clinical studies,
YAP was an independent factor in predicting a poor
disease-free survival and overall survival in HCC [25]. Sev-
eral lines of evidence from in vitro and in vivo studies have
suggested that YAP plays a critical role in hepatocarcino-
genesis. A recent study reported that a β-TrCP E3 ubiquitin
ligase regulated YAP stability through ubiquitination and
proteasomal degradation [26]. However, otherwise the
mechanisms governing YAP protein stability remain poorly
understood.
In this study, we demonstrate that Fbxw7 is an independ-
ent prognostic factor for predicting both the overall and the
disease-free 5-year survival of HCC patients. Fbxw7 acted
as a tumor suppressor by promoting both apoptosis and
growth arrest in HCC. Fbxw7 was inversely related to YAP
protein expression in HCC tissues. Interestingly, Fbxw7
interacted with YAP and catalyzed YAP ubiquitination,
ultimately leading to YAP degradation. Importantly, the
anti-cancer effect of Fbxw7 could be partially inverted by
restoring YAP expression in vitro and in vivo. Our results
suggest that Fbxw7 may target YAP for ubiquitination and
proteasomal degradation, thereby inhibiting HCC growth
and hence tumor progression.
Materials and methods
Clinical samples, cell lines and expression vectors
Sixty HCC samples and paired normal tumor-adjacent
samples (>2 cm distance from the margin of the resection)
were obtained during surgery and used after obtaining in-
formed consent. All patients underwent the resection of
their primary HCC in the Department of Hepatobiliary Sur-
gery at the First Affiliated Hospital of Xi’an Jiaotong Univer-
sity between 2006 and 2008, with a median follow-up time
of 32.5 months. The demographic features and clinicopath-
ologic data are shown in Table 1. In summary, the median
age of the patients was 52 years (range, 24–72 years).
Tumor tissue and matched normal tumor-adjacent tissue
specimens were collected and immediately stored in
paraformaldehyde for immunohistochemistry. The Xi’an
Jiaotong University Ethics Committee approved all proto-
cols according to the 1975 Helsinki Declaration.
Human HCC cell lines HepG2 and Hep3B, and 293 T
and HEK293 cells were obtained from the Institute of
Biochemistry and Cell Biology, Chinese Academy of Sci-
ences (Shanghai, China). All the cells were maintained in
Dulbecco’s modified Eagle medium (DMEM, Gibco,
Grand Island, NY, USA) containing 10% fetal bovine
serum (FBS, Gibco) with 100 units/mL penicillin and
100 μg/mL streptomycin (Sigma, St-Louis, MO, USA)
and cultured in a humidified 5% CO2 incubator at 37°C.
Table 1 Clinical correlation of Fbxw7 expression in HCC
Clinicopathologic features Total no. of
patients, n = 60
No. of patients P
Fbxw7 negative Fbxw7 positive
Age (y) <50 19 13 6 0.365
≥50 41 23 18
Sex Male 48 28 20 0.598
Female 12 8 4
HBV Absent 14 9 5 0.709
Present 46 27 19
Serum AFP level (ng/mL) <400 24 14 10 0.830
≥400 36 22 14
Tumor size (cm) <5 21 7 14 0.002*
≥5 39 29 10
No. of tumor nodules 1 45 24 21 0.068
≥2 15 12 3
Cirrhosis Absent 28 17 11 0.916
Present 32 19 13
Venous infiltration Absent 31 14 17 0.015*
Present 29 22 7
Edmondson-Steiner grading I + II 18 6 12 0.006*
III + IV 42 30 12
TNM tumor stage I + II 40 19 21 0.005*
III + IV 20 17 3
HCC, hepatocellular carcinoma; HBV, hepatitis B virus; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis. *Statistically significant.
Tu et al. Molecular Cancer 2014, 13:110 Page 3 of 13
http://www.molecular-cancer.com/content/13/1/110The pRetrosuper Fbxw7 shRNA (Plasmid #15660) was
obtained from Addgene [27]. Retroviral vectors pMMP-
Flag-Fbxw7 and pMMP-HA-YAP were generated by
inserting the respective cDNA into pMMP. All con-
structs were confirmed by sequencing and WB analysis.
The day before transfection, 5 × 106 293 T cells were
seeded in 100 mm dishes. Three plasmids, 1.5 μg pMD.
MLV, 0.5 μg pVSV.G and 2 μg relevant retroviral vec-
tors, were transfected into cells by using Effectene trans-
fection reagent (Qiagen, Valencia, CA, USA). The
medium containing the retroviruses was collected 48
and 72 hours after transfection. Viral transduction was
done by incubating cells with the viral supernatant
(25%) supplemented with polybrene (8 μg/mL) overnight
at 37°C. Further experiments were performed 48–96
hours after viral transduction.
Immunohistochemical staining
Immunohistochemistry was performed on paraformalde-
hyde-fixed paraffin sections. The following antibodies
were used in immunohistochemistry along with a
streptavidin peroxidase conjugate (SP-IHC): Fbxw7
(WH0055294M2, Sigma) (1:100), YAP (PA1-46189,
Thermo Scientific, Rockford, IL, USA) (1:100) and Ki-67 (#9027, Cell Signaling, Danvers, MA, USA) (1:400).
Immunohistochemistry was performed as previous re-
ported [15]. The percentage of positive tumor cells or hepa-
tocytes was graded as per the following criteria: 0, less than
10%; 1, 10–30%; 2, 30–50%; 3, more than 50% [25].
Real-time quantitative reverse transcription polymerase
chain reaction (qRT-PCR)
The following primers were used: YAP sense primer 5’-
CCTGCGTAGCCAGTTACCAA-3’ and antisense pri-
mer 5’-CCATCTCATCCACACTGTTC-3’ and 18S sense
primer 5’-AAACGGCTACCACATCCAAG-3’ and anti-
sense primer 5’-CCTCCAATGGATCCTCGTTA-3’. The
PCR amplification for the quantification of the Fbxw7
and YAP mRNAs and the 18S rRNA was performed
using an ABI PRISM 7300 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA) and a SYBR®
Premix Ex Taq™ ii (Perfect Real Time) Kit (Takara Bio,
Shiga, Japan), as previous reported [17].
Immunoblotting
The following primary antibodies were used in the
Western blot assays: Fbxw7 (1:1000), YAP (1:1000), Ub
(sc-8017, Santa Cruz, CA, USA) (1:500) and β-Actin (sc-
Figure 1 Expression of Fbxw7 and its clinical significance in HCC cases. A) Representative western blot analysis of Fbxw7 expression in
cancer (T) and matched noncancerous tissues (NT) was shown. Quantification of the data revealed that Fbxw7 protein expression in HCC tissues
was significantly lower than that in the normal tumor-adjacent tissues. n = 20; Values are depicted as Mean ± SEM; **P < 0.01 by t test. B) Kaplan–
Meier overall 5-year and C) disease-free survival curves for HCC patients according to their Fbxw7 protein expression status. The Fbxw7 positive
expression group (n = 24), IHC score of Fbxw7 = 1–3; Fbxw7 negative expression group (n = 36), IHC score of Fbxw7 = 0; *P < 0.05 by log-rank test.
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conjugated goat anti-mouse or anti-rabbit secondary
antibodies (Bio-Rad, Hercules, CA, USA) were used at a
1:1000–1:5000 dilution and detected using a Western
Blotting Luminol Reagent (sc-2048, Santa Cruz).Immunofluorescence (IF)
HCC cells were fixed with 3% paraformaldehyde and
permeabilized using 0.2% Triton X-100. Then the fixed cells
were incubated with the YAP (1:500) primary antibody. The
secondary antibody is an Alexa Fluor–conjugated IgG (Invi-
trogen, Carlsbad, CA, USA). Fluorescence confocal images
were captured using a LSM 5 Pascal Laser Scanning Micro-
scope (Zeiss Germany, Oberkochen, Germany) using a × 40
lens and Laser Scanning Microscope LSM PASCAL soft-






No. of tumor nodules 1.092 0.500-2.386
Tumor size 0.411 0.160-1.056
Venous infiltration 1.539 0.722-3.284
Serum AFP level 0.883 0.412-1.895
Cirrhosis 1.288 0.651-2.548
Edmondson-Steiner grading 0.771 0.322-1.846
TNM tumor stage 3.576 1.251-10.211
Fbxw7 expression in tumor 0.253 0.081-0.790
HBV, hepatitis B virus; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis; HR, hazCo-immunoprecipitation (co-IP)
HA (12CA5, Roche, Indianapolis, IN, USA) and Flag
(F1804, Sigma, USA) antibodies were used in the co-
immunoprecipitation assays. Total protein lysate was ob-
tained in immunoprecipitation buffer. The total protein
concentration of the supernatants was quantified using a
Bio-Rad DC™ Protein Assay Reagent A/B/S (Bio-Rad,
USA). 500 μg of total protein was mixed with 1 μg the pri-
mary antibody, or IgG, and the mixture were shaken on a
rotating shaker at 4°C for 2 hours. Beads (Protein G Seph-
arose 4 Fast Flow, GE Healthcare Life Sciences, Piscat-
away, NJ, USA) were added to the mixture and shaken at
4°C for 1 hour. Then the beads were collected by centrifu-
gation and washed three times by immunoprecipitation
buffer. 2× sample loading buffer was added to the beads
before boiling for 5 minutes. The supernatant was col-
lected and used in the immunoblotting assays.d disease-free 5-year survival of 60 HCC patients
Disease-free survival
P HR 95% CI P
0.091 1.670 0.787-3.545 0.182
0.474 1.031 0.492-2.162 0.936
0.219 1.971 0.827-4.696 0.126
0.824 0.889 0.438-1.805 0.744
0.065 0.481 0.211-1.098 0.082
0.264 1.892 0.940-3.808 0.074
0.749 0.953 0.483-1.880 0.889
0.468 1.313 0.711-2.423 0.384
0.560 0.702 0.338-1.458 0.342
0.017* 3.532 1.266-9.858 0.016*
0.018* 0.228 0.078-0.666 0.007*
ard ratio; CI, confidence interval. *Statistically significant.
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For the proliferation assay, HCC cells were seeded into
96-well plates at 5000 cells per well for 24 hours and
assessed using a Cell Proliferation ELISA, BrdU (5-bro-
modeoxyuridine) (chemiluminescent) (Roche, USA). The
3-(4, 5-dimethylthiazol-2-yl) 2, 5-diphenyl tetrazolium
bromide (MTT, Roche, USA) assay was used to assess
cell viability at 24, 48 and 72 hours.Cell apoptosis detection
An Annexin-V-FLUOS Staining Kit (Roche, USA) was
used to analyze the level of apoptosis, as previously de-
scribed [17]. The caspase 3/7 activity assay was con-
ducted using an Apo-ONE® Homogeneous Caspase-3/7Figure 2 Fbxw7 regulates apoptosis and proliferation in HCC cells. A)
and Fbxw7-shRNA, respectively, were subjected to western blotting for Fbx
B) Quantification of the apoptotic cell population by flow cytometry. Fbxw
apoptotic cells compared with the control cells and Fbxw7 knockdown de
n = 3 repeats with similar results. C) The activity of the pro-apoptotic caspa
cells and down-regulated after Fbxw7 knockdown in Hep3B cells. **P < 0.01
measured by BrdU incorporation was inhibited by Fbxw7 overexpression in
**P < 0.01 by t test; n = 3 repeats with similar results. E) As assessed by MTT
HepG2 cells and Fbxw7 knockdown was found to enhance the viability of
results. Values are depicted as Mean ± SEM.Assay (Promega, Madison, WI, USA), as described in
our previous study [28].
In vivo experiments
A nude mouse xenograft model was established using 4–6
week-old female BALB/c nude mice (Centre of Laboratory
Animals, The Medical College of Xi’an Jiaotong University,
Xi’an, China). Mice were housed in sterilized cages (2 ani-
mals/cage) at a constant temperature and humidity and fed
a regular autoclaved chow diet with water ad libitum [17].
As HepG2 is not a tumorigenic cell line in immunosup-
pressed mice as described in ATCC (American Type Cul-
ture Collection), 5 × 106 Hep3B cells were inoculated
subcutaneously into the flank of each nude mouse. The
tumor volume for each mouse was determined byHepG2 and Hep3B cells that had been transfected with Flag-Fbxw7
w7. The data are representative of multiple repeats with similar results.
7 overexpressing HepG2 cells were composed of a larger subset of
creased the percentage of apoptotic Hep3B cells. **P < 0.01 by t test;
ses 3 and 7 was up-regulated after Fbxw7 overexpression in HepG2
by t test; n = 3 repeats with similar results. D) Cell proliferation as
HepG2 cells and promoted by Fbxw7 knockdown in Hep3B cells.
assays, Fbxw7 overexpression was found to reduce the viability of
Hep3B cells. **P < 0.01 by two-way ANOVA; n = 3 repeats with similar
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tumor volume = length ×width ×width/2. After 3 weeks,
the mice were sacrificed by cervical dislocation under
anesthesia with ether and the xenograft tumor tissue was
explanted for routine pathological examination. The
amount of apoptosis in the isolated tumor tissues was de-
tected using a TUNEL (Terminal-deoxynucleoitidyl Trans-
ferase Mediated Nick End Labeling) assay kit (4810-30-K,
R&D Systems, Minneapolis, Minnesota, USA) according to
the manufacturer’s guidelines. All animal protocols were
approved by the Institutional Animal Care and Use Com-
mittee of Xi’an Jiaotong University.
Statistical analysis
All date are presented as the Mean ± SEM. The SPSS
statistical package for Windows Version 13 (SPSS,
Chicago, IL, USA) was used for the Pearson chi-square
tests and the multi-variant Cox regression analysis. A
two-tailed Student’s t test, a Kaplan–Meier plot, a log-
rank test, a Pearson's correlation coefficient analysis or
an ANOVA was used to evaluate statistical significance
using GraphPad Prism 5 software (GraphPad Software,
Inc, San Diego, CA, USA). P < 0.05 was considered to be
statistically significant.
Results
Clinical significance of reduced Fbxw7 expression in HCC
specimens
To investigate the clinical significance of Fbxw7 in HCC,
we tested the expression of the Fbxw7 protein by immuno-
staining in a retrospective cohort of 60 pairs of cancerous
and matched noncancerous tissue samples from HCC pa-
tients after liver resection. Fbxw7 immunoreactivity wasFigure 3 Immunohistochemical analyses of YAP and its correlation w
(D, F), there was no detectable YAP protein expression (A, C) in the same
(E), there was strong YAP protein expression (B). The fibrotic septa (B, E) si
Scale bar: 100 μm.considered as either negative (score 0) or positive (scores 1
to 3). In these 60 cases, Fbxw7 expression was detected in
43 (71.7%) of the normal tumor-adjacent tissues, whereas
only 24 (40%) of the HCC specimens showed a positive
Fbxw7 signal (P < 0.01). Furthermore, 20 cases were sub-
jected to immunoblotting for Fbxw7; we found that the
Fbxw7 protein level in HCC tissues was significantly lower
than that in the matched normal, tumor adjacent, tissues
(P < 0.01, Figure 1A). Clinical association analysis using a
Pearson chi-squared test revealed that the reduced Fbxw7
expression in HCC tissues was significantly associated with
a large tumor size (≥5 cm; P = 0.002), venous infiltration
(P = 0.015), high histological grade (Edmondson–Steiner
grade III + IV; P = 0.006) and advanced tumor stage (TNM
stage III + IV; P = 0.005) (Table 1).
Positive Fbxw7 expression correlates with a better 5-year
survival for HCC patients
A total of 60 HCC patients had complete clinical infor-
mation. To determine the role of Fbxw7 in predicting
the prognosis of HCC patients, immunohistostaining of
Fbxw7 was performed to confirm the correlation be-
tween Fbxw7 expression and 5-year patient survival. We
constructed Kaplan–Meier survival curves using the
overall 5-year patient survival date to analyze cases with
positive and negative Fbxw7 staining. Our date indicate
that overall survival in the Fbxw7 positive expression
group was 45.83%, compared with 19.44% in the nega-
tive group. In the overall survival curve, patients in the
Fbxw7 negative expression group (n = 36) had a signifi-
cantly poorer prognosis than those in the Fbxw7 positive
expression group (n = 24; log-rank = 5.850; P = 0.0156;
Figure 1B). The median disease-free survival times in theith Fbxw7 protein in HCC. In cases of high Fbxw7 protein expression
tissue section. In contrast, in the case of low Fbxw7 protein expression
mply represent fibrotic tumor stroma with normal background liver.
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were 32.5 months and 15.0 months, respectively.
Kaplan–Meier analysis also revealed that Fbxw7 loss was
associated with a short disease-free survival time (log-
rank = 4.643; P = 0.0312; Figure 1C). These data suggest
that Fbxw7 may function as a potential prognostic
marker in HCC. Furthermore, Fbxw7 expression is an
independent factor for predicting both 5-year overall
and disease-free survival in HCC patients (P = 0.018 and
0.007, respectively; Table 2).
Fbxw7 inhibits proliferation and induces apoptosis in
HCC cells
Our previous studies have shown that Fbxw7 knockdown
in HCC cells, using a siRNA, enhanced cell viability and
partially abolished p53-induced apoptosis [17]. We thus
sought to determine whether Fbxw7 acted as a tumorFigure 4 Fbxw7 regulates the stability of the YAP protein in HCC cell
and Fbxw7-shRNA, respectively, and subjected to Western blotting for Fbxw
Cyclin E and YAP protein levels in HepG2 cells, whereas Fbxw7 knockdown
representative of multiple repeats with similar results. B) HepG2 cells transf
non-targeting (NT)-shRNA or Fbxw7-shRNA were harvested for RNA extract
change YAP mRNA levels. n = 3 independent experiment; Values are depict
subjected to IF for YAP. Quantification of YAP immunofluorescence reveale
higher than that in the Fbxw7 overexpressing HepG2 cells and lower than
n = 6; Values are depicted as the Mean ± SEM; **P < 0.01 by t test.suppressor in HCC in a similar fashion, i.e. by promoting
apoptosis and inhibiting cell proliferation. As assessed by
western blotting analysis, the Fbxw7 protein level could be
raised by ectopically expressing a flag tagged Fbxw7 (Flag-
Fbxw7) or reduced using an Fbxw7 shRNA, in HepG2 and
Hep3B cells respectively (Figure 2A). As determined by
flow cytometry, apoptosis assays and caspase 3/7 activity
assays, Fbxw7 overexpression induced apoptosis in HepG2
cells and Fbxw7 knockdown prevented Hep3B cells from
undergoing apoptosis (P < 0.01, respectively, Figure 2B and
C). BrdU and MTTassays were performed to test the effect
of altering Fbxw7 levels on tumor cell proliferation and via-
bility, respectively. As expected, Fbxw7 overexpression
inhibited proliferation and viability in HepG2 cells and
Fbxw7 knockdown promoted the proliferation and viability
of the Hep3B cells (P < 0.01, for both assays, Figure 2D and
E). Hep3B has higher basal expression of Fbxw7 thans. A) HepG2 and Hep3B cells that were transfected with Flag-Fbxw7
7, c-Myc, Cyclin E and YAP. Fbxw7 overexpression decreased c-Myc,
led to c-Myc, Cyclin E and YAP accumulation in Hep3B cells. Data are
ected with EV or Flag-Fbxw7 and Hep3B cells transfected with
ion and real time RT-PCR. Fbxw7 overexpression or knockdown did not
ed as the Mean ± SEM. C) HCC cells that were treated as above were
d that the average level of YAP in the control cells was significantly
that in the Fbxw7 shRNA transfected Hep3B cells. Scale bar: 20 μm,
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baseline apoptosis and more proliferation as well as viability
than Hep3B (Figure 2). Thus, Fbxw7 exerts an anti-HCC
effect by promoting both apoptosis and growth arrest.
Fbxw7 inversely correlates with YAP protein in HCC
tissues
Since YAP overexpression has been reported in HCC [25],
we examined the correlation between Fbxw7 and YAP in
serial sections of 60 HCC cases by immunohistochemical
study. YAP immunoreactivity was considered as either
negative (score 0) or positive (scores 1 to 3). The expression
of YAP protein in cancer tissues was significantly higher
than those in paired noncancerous tissues [63.3% (38/60) vs
11.7% (7/60); P < 0.01]. Furthermore, IHC scores were used
for semiquantitative analysis of Fbxw7 and YAP expression,
we found a strong inverse correlation between Fbxw7 and
YAP in HCC tissues (r = −0.572; P = 0.003; Figure 3).
Fbxw7 regulates YAP abundance in HCC cells
To investigate the downstream factor(s) involved in
Fbxw7-mediated apoptosis and growth arrest in HCC;
HepG2 and Hep3B cells were transfected with Flag-Fbxw7
and Fbxw7-shRNA respectively. Western blotting analysis
was performed to detect c-Myc, Cyclin E and YAP. c-Myc
and Cyclin E are both confirmed target proteins of Fbxw7.
YAP functions as a transcriptional coactivator involved in
the regulation of cell growth, proliferation, and apoptosis
[19]. Fbxw7 knockdown led to c-Myc and Cyclin EFigure 5 Fbxw7 binds to YAP and promotes the ubiquitin-mediated p
each other. Flag-Fbxw7 and HA-YAP plasmids were transfected into HEK29
Flag antibody. Western blotting was performed to detect the specific prote
precipitated from HA-YAP overexpressing HepG2 cells by immunoprecipita
western blotting. Fbxw7 overexpression markedly promoted YAP ubiquitin
HepG2 cells. The protein half-life of YAP was analyzed following treatment
and then normalized to t = 100 controls. The half-life of YAP in Flag-Fbxw7
with MG132 (a proteasome inhibitor) inhibited Fbxw7 induced YAP degradat
experiments.accumulation in Hep3B cells and Fbxw7 overexpression
decreased the levels of both proteins in HepG2 cells
(Figure 4A). These results are consistent with those of our
prior study [17]. Interestingly, we found that Fbxw7 over-
expression also decreased YAP protein levels in HepG2
cells and that Fbxw7 knockdown increased the level of this
protein in Hep3B cells (Figure 4A), whereas YAP mRNA
levels were only either slightly decreased or slightly in-
creased, without statistically significant (Figure 4B). Fur-
thermore, IF for YAP indicated that the average level of
YAP in Flag-Fbxw7 transfected HepG2 cells was signifi-
cantly lower than that in control cells (P < 0.01, Figure 4C).
Conversely, the average level of YAP in Fbxw7-shRNA
transfected Hep3B cells was significantly higher than that
in control cells (P < 0.01, Figure 4C). These data indicate
that Fbxw7 reduces YAP protein levels in HCC cells.
Fbxw7 promotes the ubiquitination and proteasomal
degradation of YAP
Because Fbxw7 is an ubiquitin ligase that targets several
oncoproteins for proteolysis and YAP is known to be
subjected to ubiquitin modification by β-TrCP [1,26], we
sought to determine whether Fbxw7 binds to YAP and
leads to its ubiquitination and proteasomal degradation.
To this end, the interaction between Fbxw7 and YAP
was confirmed in HEK293 cells by reciprocal co-IP of
HA-YAP and Flag-Fbxw7 (Figure 5A). HA-YAP was pre-
cipitated from HepG2 cells expressing HA-YAP, and
YAP ubiquitination was detected by an ubiquitin westernroteolysis of YAP. A) YAP and Fbxw7 coimmunoprecipitate with
3 cells. YAP or Fbxw7 was immunoprecipitated with anti-HA or anti-
ins indicated on the left side of each panel. B) HA-YAP was
tion using an anti-HA antibody; YAP ubiquitination was detected by
ation. C) The Fbxw7 turnover rate was shorter in Fbxw7 overexpressing
with cycloheximide. The YAP band intensity was normalized to GAPDH
= 5.2 h (R2 = 0.96) and in EV = 16.5 h (R2 = 0.92). Additionally, treatment
ion in HepG2 cells. The data are representative of multiple independent
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markedly increased the ubiquitination of YAP in HepG2
cells. We next used a CHX (Cycloheximide, a protein
synthesis inhibitor) chase assays to analyze the Fbxw7
mediated downregulation of YAP in both control and
Fbxw7 overexpression HepG2 cells. To this end, the
half-life of YAP was substantially decreased in Fbxw7-
overexpressing cells, compared with that seen in the
control cells (5.2 h vs 16.5 h, Figure 5C). Additionally,
the proteasome inhibitor MG132 was able to prevent
the downregulation of YAP (Figure 5C). Thus, these data
support a model whereby Fbxw7 binds to YAP and
thereby promotes the ubiquitination and proteasomal
degradation of YAP.
Fbxw7 inhibits proliferation and induces apoptosis
through promoting YAP degradation in HCC
To determine whether the YAP protein participates in
Fbxw7 induced apoptosis and growth arrest in HCC cells,
Fbxw7 overexpressing Hep3B cells were subsequently
transfected with HA-YAP. Restoring YAP expression in
Hep3B cells partially reverted the effect of exogenousFigure 6 Fbxw7’s suppression of Hep3B cell growth was partially reve
regulated Fbxw7 protein expression as shown by western blot. Fbxw7 ove
over-expressing cells that were transfected with HA-YAP partially rescued t
of multiple repeats with similar results. B) Apoptotic cells were measured b
of apoptotic cells in Flag-Fbxw7 transfected Hep3B cells. **P < 0.01 by one-
pro-apoptotic caspases 3 and 7 in Fbxw7 overexpressing Hep3B cells was d
repeats with similar results. D) A BrdU assay showed that YAP promotes pr
ANOVA; n = 3 repeats with similar results. E) YAP was found to enhance th
by two-way ANOVA; n = 3 repeats with similar results. Values are depictedFbxw7 overexpression, leading to a significant reduction in
the number of apoptotic cells as well as increased cell pro-
liferation and viability (P < 0.01, respectively, Figure 6). We
next sought to determine whether Fbxw7 affects tumor
growth by inhibiting YAP using a Hep3B subcutaneous
tumor model. Hep3B cells that had been infected with dif-
ferent retroviruses were implanted into nude mice via sub-
cutaneous injection. Tumor growth curves, generated over
21 days, revealed that Fbxw7 overexpression slowed down
Hep3B tumor growth in mice. Restoring YAP expression
partially restored tumor growth, for the Fbxw7-
overexpressing Hep3B cells (P < 0.01, Figure 7A). We per-
formed immunohistochemistry for YAP and Ki-67 as well
as TUNEL assays in the xenografted tissues. As expected,
Fbxw7 overexpression down-regulated YAP protein expres-
sion, inhibited proliferation and induced apoptosis in vivo.
YAP partially abolished the inhibiting effect of Fbxw7 on
HCC growth; it led to a significant reduction in the number
of apoptotic cells and increased the number of cells staining
positive for Ki-67, which is consistent with our in vitro ob-
servations (P < 0.05 or P < 0.01, respectively, Figure 7B).
Taken together, these data indicate that YAP may functionrted by YAP. A) Flag-Fbxw7 transfected Hep3B cells successfully up-
rexpression in the same cell line could reduce the levels of YAP. Fbxw7
he phenotype, showing higher YAP levels. The data are representative
y flow cytometry. Restoring YAP expression decreased the percentage
way ANOVA; n = 3 repeats with similar results. C) The activity of the
ecreased by HA-YAP transfection. **P < 0.01 by one-way ANOVA; n = 3
oliferation in Fbxw7 overexpressing Hep3B cells. **P < 0.01 by one-way
e viability of Fbxw7 over-expressing Hep3B cells (MTT assay). **P < 0.01
as the Mean ± SEM.
Figure 7 YAP partially abolishes Fbxw7’s suppression of tumor growth. A) Control Hep3B cells (EV, n = 6), Fbxw7 overexpressing Hep3B
cells (Flag-Fbxw7, n = 6) and co-expressing Hep3B cells (Flag-Fbxw7 + HA-YAP, n = 6), respectively, were implanted into nude mice via subcutaneous
injection. Tumor nodules were measured using a caliper at different times after implantation. Fbxw7 overexpressing Hep3B cells exhibited a greater
tumor-inhibiting effect compared with control cells; however, restoring YAP expression accelerated tumor growth, compared with the Flag-Fbxw7
group. **P < 0.01 by two-way ANOVA. B) Tumor nodules were subjected to immunohistochemical staining for YAP and Ki-67, TUNEL assays and
quantitative analysis. Representative immunostaining and TUNEL assays revealed that Fbxw7 overexpression significantly reduced the number of YAP
and Ki-67 positive cells and increased the number of apoptotic cells. However, the percentage of YAP and Ki-67 positive cells in tumors arising from
the Flag-Fbxw7 + HA-YAP group was significantly higher than that in the tumors from the Flag-Fbxw7 group and the percentage of apoptotic cells in
the Flag-Fbxw7 + HA-YAP group was significantly lower than that in the Flag-Fbxw7 group. Black arrows indicate positive cells in each photomicrograph.
Scale bar: 100 μm; n = 6; Values are depicted as the Mean ± SEM; *P < 0.05 and **P < 0.01 by one-way ANOVA.
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growth arrest in HCC.
Discussion
As a general tumor suppressor, both Fbxw7 mRNA and
protein expression levels have been shown to be down-
regulated in various cancers [10]. Additionally, dysfunc-
tional mutations of Fbxw7 have been found in several
malignancies and the total mutation rate was reportedas 6% [11]. We initially investigated the expression of
the Fbxw7 protein in 60 HCC patients using immuno-
histochemistry and western blotting, and our data
showed that the expression of Fbxw7 was significantly
lower in HCC compared with matched normal tumor-
adjacent tissues. Furthermore, Fbxw7 expression was sig-
nificantly correlated with tumor size, venous infiltration,
Edmondson–Steiner grading and TNM tumor stage,
which is consistent with our previous study [15,16].
Figure 8 Working model for the tumor suppressive function of
Fbxw7 and its downstream pathway. Fbxw7 promotes both
apoptosis and the growth arrest of HCC through promoting YAP
ubiquitination and proteasomal degradation.
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pression is significantly correlated with a better 5-year
patient survival for all HCC patients, which is consistent
with the previous studies on gastric cancer, colorectal
cancer, glioma and melanoma [12,14,29,30]. Otherwise,
multivariate Cox repression analysis found that Fbxw7 is
an independent factor in predicting both overall 5-year
survival and disease-free survival in HCC patients. These
results show that the status of Fbxw7 is critical for prog-
nosis determination in HCC patients. Our previous
study showed that Fbxw7 functions as a tumor suppres-
sor and that it may be involved in apoptosis and prolifer-
ation in HCC [17]. In this study, we have further
confirmed that Fbxw7 suppresses tumor progression by
promoting apoptosis and growth inhibition in HCC.
It has been reported that Fbxw7 is responsible for the
degradation of several substrates, which are involved in
apoptosis and cell proliferation regulation, such as c-Myc,
Cyclin E, Notch1 and MCL-1 [2,3,7,8]. Our previous study
reported that Fbxw7 levels were inversely correlated with
those of c-Myc and Cyclin E in HCC tissues [15]. Addition-
ally, Fbxw7 knockdown by siRNA led to an accumulation
of c-Myc and Cyclin E in HCC cells [17]. In this study, we
confirmed that YAP expression in HCC was obviously
higher as compared with those in normal tumor-adjacent
tissues. Otherwise, Fbxw7 was inversely associated with
YAP protein expression in HCC tissues. In vitro studies, we
found that Fbxw7 negatively regulates c-Myc and Cyclin E
abundance in HCC cells. Interestingly, we found that
Fbxw7 overexpression significantly decreased YAP levels in
HepG2 cells. Conversely, the ablation of Fbxw7 by shRNA
in Hep3B, a cell line with high expression of the target
gene, consistently showed an accumulation of YAP. But
YAP mRNA levels did not change significantly with Fbxw7
regulation, suggesting that Fbxw7 regulates the abundance
of the YAP protein in HCC cells. It has been reported that
the β-TrCP E3 ubiquitin ligase catalyzed YAP ubiquitina-
tion, ultimately leading to YAP degradation [26]. In our
study, we confirmed the interaction between Fbxw7 and
YAP in HEK293 cells using co-immunoprecipitation. Fur-
thermore, co-IP and western blot indicated that Fbxw7 pro-
motes YAP ubiquitination and shortens the half-life of YAP
in HepG2 cells, and that MG132 treatment could inhibit
YAP’s downregulation by Fbxw7. The data we present in
this study indicate that Fbxw7 mediates the ubiquitination
of YAP, and thus its subsequent proteasomal degradation.
In most cases, phosphorylation of the F-box recognition
motif present on the substrate, more commonly known as
a phosphor-degron, is necessary before efficient substrate/
ligase interaction [31]. Therefore, further investigation is re-
quired to confirm whether YAP is a bona fide target of
Fbxw7 and a proteomic data with searches for YAP with
the Fbxw7 canonical phospho-degron may address this
question.Here we showed Fbxw7 overexpression using a retro-
virus, which resulted in the downregulation of YAP
in vitro and in vivo. This and the observed increase in
apoptosis and growth arrest could be partially reverted
by treatment by retrovirus-mediated YAP overexpres-
sion. However, only 30%–35% of the effect of Fbxw7 on
inhibiting HCC cells was abolished, despite achieving
more than a 70% restoration in the levels of YAP, sug-
gesting that YAP is not the unique downstream effector
of Fbxw7 induced apoptosis and growth arrest in HCC.
Fbxw7 targets various oncoproteins for ubiquitination
and degradation and these substrates play important
roles in regulating apoptosis, cell cycle, cell division, cell
proliferation [1]. We suggest that Fbxw7 triggers apop-
tosis and growth arrest likely through affecting several
downstream targets. Nevertheless, Fbxw7 mediated YAP
degradation might account for apoptosis and growth ar-
rest in HCC.
In conclusion, we demonstrate that reduced levels of
Fbxw7 are associated with poor clinicopathological
characteristics in HCC tissues. The negative expression
of Fbxw7 is an independent factor for predicting poor
prognosis in HCC patients. Fbxw7 induces apoptosis
and growth arrest by promoting the ubiquitination and
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in vitro and in vivo (Figure 8). Altogether, we
hypothesize that loss of Fbxw7 function contributes to
hepatocarcinogenesis, in part through the accumulation
of YAP. By addressing this pathway, we identified Fbxw7
as a potential therapeutic target for HCC.Conclusions
In summary, this study shows that Fbxw7 expression is
impaired in cancer tissues as compared with noncancer-
ous tissues and that reduced Fbxw7 levels are correlated
with poor clinicopathological features in HCC. Further-
more, we demonstrate that Fbxw7 is an independent fac-
tor for predicting the overall 5-year survival and disease-
free survival of HCC patients. In vitro studies found that
Fbxw7 inhibits HCC growth via inducing apoptosis and
growth arrest. Elevated YAP expression is observed in
HCC tissues and its expression is inversely associated
with Fbxw7. Importantly, our data, for the first time, in-
dicate that Fbxw7 inversely regulates YAP protein abun-
dance by promoting YAP for ubiquitination and
proteasomal degradation in HCC. Our results confirm
that YAP is a candidate oncogene because it plays a crit-
ical role in hepatocarcinogenesis. Interestingly, restoring
YAP can partially abolish the effect of Fbxw7 on anti-
HCC, suggesting that Fbxw7 may exert its tumor sup-
pressive function by regulating the stability of the YAP
protein. This study reveals a potential target of Fbxw7
and supplies us with a new insight into the accumulation
of YAP in HCC. Fbxw7 may potentially act as a clinical
biomarker, and may also be a therapeutic target, in
HCC.
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